Mounjaro for weight loss does not commonly cause permanent eye issues, but some patients report blurred vision during the initial phase of treatment
Some protocols use a 'loading' phase (higher dose for 35 days) followed by maintenance dosing (lower dose long-term), based on the hypothesis that initial synaptogenesis requires stronger signaling, while maintaining new synapses requires less
At TrimRx, we believe that education is the first step toward a successful and sustainable health transformation
What's New: July 2026 Update TRIUMPH-4 confirmed: 28.7% weight loss at 68 weeks in 445 participants topline results announced December 2025 TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients the pivotal general obesity trial met all primary and key secondary endpoints TRIUMPH-1 extension: In a prespecified 104-week extension, patients with BMI 35 reached 30.3% average weight loss no plateau observed TRANSCEND-T2D-1 confirmed (topline March 2026, published June 2026): First dedicated Phase 3 diabetes trial -2.0% HbA1c and 16.8% weight loss in 537 type 2 diabetes patients OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour TRIUMPH-2 (obesity + diabetes) and TRIUMPH-3 (obesity + cardiovascular disease) results expected later in 2026 Efficacy Summary Across All Completed Trials Phase 2: The Foundation (2023) The Phase 2 trial, published in the New England Journal of Medicine in June 2023, evaluated retatrutide in 338 adults with obesity (BMI 30) or overweight (BMI 27) with weight-related comorbidities
A thorough consultation will determine your eligibility.
Without Phase II, every Phase I metabolite would accumulate as a free radical, causing more damage than the original toxin
